1. Home
  2. SRRK

as of 02-06-2026 4:00pm EST

$47.62
+$3.17
+7.13%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.

Founded: 2012 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 4.6B IPO Year: 2018
Target Price: $51.20 AVG Volume (30 days): 1.0M
Analyst Decision: Strong Buy Number of Analysts: 11
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.56 EPS Growth: N/A
52 Week Low/High: $22.71 - $49.82 Next Earning Date: 02-26-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 20029.43%
P/E Ratio: N/A Index: N/A
Free Cash Flow: -274644000.0 FCF Growth: N/A

AI-Powered SRRK Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 69.13%
69.13%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Scholar Rock Holding Corporation (SRRK)

Qatanani Mo

CHIEF SCIENTIFIC OFFICER

Sell
SRRK Jan 22, 2026

Avg Cost/Share

$46.36

Shares

14,898

Total Value

$695,937.54

Owned After

85,660

Qatanani Mo

CHIEF SCIENTIFIC OFFICER

Sell
SRRK Jan 16, 2026

Avg Cost/Share

$44.48

Shares

8,406

Total Value

$373,879.55

Owned After

85,660

SEC Form 4

SRRK Jan 16, 2026

Avg Cost/Share

$44.48

Shares

6,600

Total Value

$293,552.82

Owned After

148,864

SEC Form 4

Ho Junlin

GENERAL COUNSEL

Sell
SRRK Jan 16, 2026

Avg Cost/Share

$44.48

Shares

8,016

Total Value

$356,533.24

Owned After

214,553

SEC Form 4

Marantz Jing L.

CHIEF MEDICAL OFFICER

Sell
SRRK Jan 16, 2026

Avg Cost/Share

$44.48

Shares

5,798

Total Value

$257,881.70

Owned After

95,687

SEC Form 4

Qatanani Mo

CHIEF SCIENTIFIC OFFICER

Sell
SRRK Jan 14, 2026

Avg Cost/Share

$45.20

Shares

13,112

Total Value

$592,611.26

Owned After

85,660

SEC Form 4

Woods Keith

Chief Operating Officer

Sell
SRRK Jan 13, 2026

Avg Cost/Share

$42.70

Shares

16,746

Total Value

$715,054.20

Owned After

583,254

SEC Form 4

Sinha Vikas

Chief Financial Officer

Sell
SRRK Jan 13, 2026

Avg Cost/Share

$42.70

Shares

16,755

Total Value

$715,438.50

Owned After

583,245

SEC Form 4

Hallal David

Chief Executive Officer

Sell
SRRK Jan 13, 2026

Avg Cost/Share

$42.70

Shares

57,450

Total Value

$2,453,115.00

Owned After

1,541,645

SEC Form 4

Vaishnaw Akshay

President of R&D

Sell
SRRK Jan 13, 2026

Avg Cost/Share

$42.70

Shares

20,438

Total Value

$872,702.60

Owned After

595,767

SEC Form 4

Latest Scholar Rock Holding Corporation News

SRRK Breaking Stock News: Dive into SRRK Ticker-Specific Updates for Smart Investing

All SRRK News

Share on Social Networks: